Upcoming event

NIVOREN-GETUG AFU-26 trial

2020-02-20

Dr. Colomba on “Is body mass index (BMI) associated with favorable outcomes in metastatic renal cell carcinoma (mRCC) treated with nivolumab? An ancillary study of the NIVOREN-GETUG AFU-26 trial.”